Vertex Announces Provisional Agreement with
Pharmac for the reimbursement of TRIKAFTA®
(elexacaftor/tezacaftor/ivacaftor and ivacaftor) for
Patients With Cystic Fibrosis Ages 6 Years and Older With at
Least One F508del
Mutation in the
CFTR
Gene
– Under this agreement, more than 360
New Zealanders with cystic fibrosis will have funded access
to Trikafta, including around 340 who will have reimbursed
access to a CFTR modulator therapy for the first time
–
Wellington – 4 November 2022 – Vertex
Pharmaceuticals today announced that it has reached a
provisional agreement with New Zealand’s medicines
purchasing agency, Pharmac, for the reimbursement of
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor).
Following a public consultation period, the agreement will
cover eligible cystic fibrosis (CF) patients 6 years and
older who have at least one F508del mutation in the
cystic fibrosis transmembrane conductance regulator
(CFTR) gene with access planned from 1 April
2023.
“Today’s announcement is a significant
milestone in ensuring New Zealanders living with cystic
fibrosis receive timely and sustainable access to Trikafta,
including children as young as six,” said Sabrina Barbic,
Senior Country Manager, Vertex Australia and New Zealand.
“We are pleased that Pharmac has recognised that every
eligible patient should have access and acknowledges the
value Trikafta can bring, not only to people living with
cystic fibrosis and their caregivers, but also the wider
society.”
Pharmac will now seek public consultation
on its proposal to fund Trikafta. We acknowledge this as an
important step in the process and are hopeful that patients
will have access to Trikafta as soon as possible.
On
finalisation of the process, New Zealand will join more than
thirty-five other countries – including Australia, Canada,
Denmark, Finland, Spain, Germany, Austria, Slovenia,
Croatia, France, Italy, and the United Kingdom – where
Trikafta is broadly reimbursed for eligible CF
patients.
About TRIKAFTA®
(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
In
people with certain types of mutations in the CFTR gene, the
CFTR protein is not processed or folded normally within the
cell, and this can prevent the CFTR protein from reaching
the cell surface and functioning properly. TRIKAFTA®
(elexacaftor/tezacaftor/ivacaftor and ivacaftor) is an oral
medicine designed to increase the quantity and function of
the CFTR protein at the cell surface. Elexacaftor and
tezacaftor work together to increase the amount of mature
protein at the cell surface by binding to different sites on
the CFTR protein. Ivacaftor, which is known as a CFTR
potentiator, is designed to facilitate the ability of CFTR
proteins to transport salt and water across the cell
membrane. The combined actions of elexacaftor, tezacaftor
and ivacaftor help hydrate and clear mucus from the
airways.
About TRIKAFTA®
(elexacaftor/tezacaftor/ivacaftor and ivacaftor) in New
Zealand
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor
and ivacaftor) is a prescription medicine approved for the
treatment of cystic fibrosis (CF) in patients ages 6 years
and older who have at least one copy of
theF508delmutation in the CFTR gene.
TRIKAFTA has risks and benefits. Use strictly as directed.
TRIKAFTA is currently an unfunded medicine – a prescription
charge will apply.
- Consumer Medicine information
can be obtained from the Medsafe website www.medsafe.govt.nz - Prescribing
Information (TRIKAFTA New Zealand Data Sheet) for healthcare
professionals can be obtained from the Medsafe website www.medsafe.govt.nz
About
Cystic Fibrosis
Cystic fibrosis (CF) is a rare,
life-shortening genetic disease affecting more than 80,000
people globally. CF is a progressive, multi-system disease
that affects the lungs, liver, GI tract, sinuses, sweat
glands, pancreas and reproductive tract. CF is caused by a
defective and/or missing CFTR protein resulting from certain
mutations in the CFTR gene. Children must inherit two
defective CFTR genes — one from each parent — to
have CF. While there are many different types of CFTR
mutations that can cause the disease, the vast majority of
all people with CF have at least one F508del
mutation. These mutations, which can be determined by a
genetic test, or genotyping test, lead to CF by creating
non-working and/or too few CFTR proteins at the cell
surface. The defective function and/or absence of CFTR
protein results in poor flow of salt and water into and out
of the cells in a number of organs. In the lungs, this leads
to the buildup of abnormally thick, sticky mucus that can
cause chronic lung infections and progressive lung damage in
many patients that eventually leads to death. The median age
of death is in the early 30s.
About
Vertex
Vertex is a global biotechnology company that
invests in scientific innovation to create transformative
medicines for people with serious diseases. The company has
multiple approved medicines that treat the underlying cause
of cystic fibrosis (CF) — a rare, life-threatening genetic
disease — and has several ongoing clinical and research
programs in CF. Beyond CF, Vertex has a robust pipeline of
investigational small molecule, cell and genetic therapies
in other serious diseases where it has deep insight into
causal human biology, including sickle cell disease, beta
thalassemia, APOL1-mediated kidney disease, pain, type 1
diabetes, alpha-1 antitrypsin deficiency and Duchenne
muscular dystrophy.
Founded in 1989 in Cambridge,
Mass., Vertex’s global headquarters is now located in
Boston’s Innovation District and its international
headquarters is in London. Additionally, the company has
research and development sites and commercial offices in
North America, Europe, Australia and Latin America. Vertex
is consistently recognized as one of the industry’s top
places to work, including 13 consecutive years on Science
magazine’s Top Employers list and one of Fortune’s Best
Workplaces in Biotechnology and Pharmaceuticals and Best
Workplaces for
Women.
© Scoop Media



















Discussion about this post